Form 4: Astera Labs Director Bethany Mayer Executes Pre-Planned Stock Sales and Family Trust Transfer

Astera Labs Director Bethany Mayer reported the sale of 686 shares of common stock under a Rule 10b5-1 trading plan and the transfer of 839 shares to a family trust.

Summary

• Astera Labs, Inc. (ALAB) Director Bethany Mayer reported changes in her beneficial ownership of common stock through a recent SEC Form 4 filing.
• On June 24, 2025, Ms. Mayer sold a total of 686 shares of common stock in three separate transactions.
• The sales were executed at weighted average prices of $86.8098 (261 shares), $87.6454 (312 shares), and $88.5011 (113 shares).
• These sales were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted by Ms. Mayer on November 25, 2024.
• On June 26, 2025, Ms. Mayer transferred 839 shares of common stock to The Jantzen/Mayer Family 2002 Trust for no consideration.
• Following these transactions, Ms. Mayer directly owns 5,399 shares and indirectly owns 839 shares through the Trust, for which she disclaims beneficial ownership except for her pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider sales can sometimes be viewed negatively, the fact that they were conducted under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The transfer to a family trust is a common estate planning move and not indicative of company performance.

Positives

• The sales of common stock were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions and reducing concerns about opportunistic insider selling.

Negatives

• A director selling shares reduces their direct equity stake in the company, which can sometimes be perceived negatively by investors.

Risks

• No specific risks beyond the general perception of insider sales are mentioned in the document.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide information related to broader industry trends or competitors.

Comparison to Industry Standards

• This document, being a Form 4 filing, reports individual insider transactions and does not contain information suitable for comparison to global industry benchmarks, comparable companies, projects, or results.

Related Party Transactions

• The transfer of 839 shares of common stock to The Jantzen/Mayer Family 2002 Trust, of which the Reporting Person is a trustee, is a related party transaction.

Stakeholder Impact

• Shareholders: The director's direct equity stake is reduced, but overall beneficial ownership (direct + indirect) remains significant. The pre-planned nature of sales may reduce negative perception.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Astera Labs, ALAB, Form 4, insider trading, stock sale, beneficial ownership, Rule 10b5-1 plan, director transactions, equity transfer, family trust